Introduction
The major concerns in epilepsy management during pregnancy are due to potentials hazards of seizures for both mother and fetus and on the other hand, the teratogenicity of the antiepileptic drugs (AEDs). 1 So far, lamotrigine monotherapy specially in low doses is believed to be a reasonable choice in the management of epilepsy during pregnancy. [2] [3] [4] This is a result of its negligible effect on the fetus and in the meantime, rather acceptable efficacy in controlling seizures. [2] [3] [4] Although Human Pregnancy Registry reports have described some adverse effects for lamotrigine, the mentioned risks seem to be no more than normal population, especially in doses less than 200 mg/day. Besides, studies have suggested a dose dependent nature (more than 400 mg/day) for the side effects. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] On the other hand, neurologists face the dilemma of reducing the dose of lamotrigine in pregnancy and the concern about seizure recurrence. This is because of the fact that the serum level of the drug decreases in this period. 16, 17 To our knowledge, there was little data on the other possible pregnancy outcomes such as twin pregnancy, which prompted us to report our observations on 20 pregnant patients under lamotrigine monotherapy regimen.
Patients and methods
This study was conducted in the outpatient clinic for seizure in Sina University Hospital, Tehran, Iran 2005-2008. Here we observed 20 epileptic women (16 with primary generalized, 4 with focal seizures) during the pregnancy period and the following 8 months after delivery. All of our patients were only receiving lamotrigine prior to conception and during their pregnancy as the antiepileptic drug. Other potentially harmful medications were all discontinued. The necessary dosages to obtain seizure-free state were administered before pregnancy. Our attempt was to use the minimum possible dose. If any of our patients would experience relapses during pregnancy, she would have necessary dose adjustment and a gynecologic evaluation. All patients received folic acid supplement (5 mg/day) prior to and during pregnancy. Ultrasounds were done in the first trimester and according to gynecologist opinion. EEG studies were obtained prior during and after pregnancy. Pediatricians examined newborns for birth defects.
The study was approved by the ethic committee of the hospital. The confidentiality of data were ensured and no intervention was applied in this study.
Results
Our patients aged 25.2 AE 3.1 years (mean AE S.D.). Eighteen were primigravida. None of them had a history of infertility neither were using assisted reproduction technology (ART). Lamotrigine is frequently used to manage epilepsy during pregnancy. However, some major and minor birth defects are reported with lamotrigine monotherapy. This study is a case series report on 20 epileptic women who were receiving lamotrigine in their pregnancy. Apart from the normal pregnancies and births, in our study three patients gave birth to healthy twins, two vanished twin syndromes occurred and one patient had abortion. Twin pregnancy in association with lamotrigine therapy has not been clearly described before. Our observational study raises the idea that lamotrigine may induce twin pregnancy but larger studies need to investigate the presence or absence of such association more decently.
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Six had primary generalized seizure with myoclonus, 10 had primary generalized seizure without myoclonus, and three had secondary generalized and one complex partial seizure, which were all well controlled. Eleven had normal EEGs before pregnancy, seven had bilateral and two had lateralised epileptiform discharges in their EEG studies. The mean AE S.D. of the lamotrigine dose to control seizures before pregnancy was 270 AE 71 mg/day. The highest dose was 400 mg/day, which was administered to only one patient. In two patients who developed an episode of generalized seizure, we needed to readjust the lamotrigine dose to higher levels (both from 250 to 300 mg/day).
We used the final doses in the analyses. During the pregnancy, two patients did not attach to the prescribed regimen and discontinued their medication, however they had no seizures and no complications in their pregnancy till the end of the study. None of them had a twin pregnancy. Fourteen (70%) were seizure free during their pregnancy, four (20%) had one generalized tonic clonic seizure and two experienced myoclonus. The EEG studies were normal in nine (45%), bilateral involvement in eight (40%) and lateralised abnormality in three (10%) patients.
Fourteen patients (70%) carried on a normal pregnancy and delivered full term healthy babies. three had twin pregnancies, which progressed normally and ended in healthy birth. two of them were similar twins and the other was dissimilar; two of them had strong family histories of twin pregnancy as the major predisposing factor (Table 1) . In two patients, ultrasound studies in the first trimester showed twin pregnancies, but was not continued to the third trimester and ended in the birth of one healthy baby in both (vanished twin syndrome). None of them had a family history or past medical history of twin pregnancies or vanished twin syndrome. The gynecological evaluations revealed no specific complication. One patient experienced spontaneous abortion in the 8th week. Although she had no history of infertility formerly, she needed ART to get pregnant afterwards. None of the newborns had either a major or a minor birth defect.
Discussion
So far, the human and animal studies suggest that lamotrigine, especially in lower doses (200 mg/day), seems to be the safer than other AED monotherapy or polytherapies. [1] [2] [3] [4] 8, 10 Nevertheless, complications such as abortion, stillbirth and congenital malformations have been reported. The risk of such outcomes have been estimated to be no more than 1-2.9% in different studies, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] which in the mean time is more likely when the administered doses are higher (500 mg/day). 18 In this study, the majority of patients (70%) went through a normal pregnancy and delivered healthy babies. Fortunately no congenital malformation was encountered, which is justifiable considering the small risk in our small number of cases. In addition, most of our patients (70%) remained seizure free with lamotrigine monotherapy and higher doses (500 mg/day) were not needed to control the seizures.
To our knowledge, there is no clear report about twin pregnancy with lamotrigine. The risk of twin pregnancy is nearly 13/1000 in population and the family history of twin pregnancy and ART are the major risk factors for it. 19 However, there were five twin pregnancies in our study, from which three ended in the birth of healthy twins; two of them had strong family history of twin pregnancies.
The clear positive family history in these two cases may explain the findings.
On the other hand, the two other patients with twin pregnancy, who finally gave birth to single babies, had no positive family history. The vanished twin syndrome, which occurred in these two patients, is believed to happen in 20 to 50% of twin pregnancies. 20 As expected the remaining fetuses in these two cases were normal. Abortion may occur in approximately 15% of pregnancies 21,22 ; there are reports of 4-6.5% abortion in exposure to AED. 6, 11 In this study, one abortion took place in the 8th week of gestation. No obvious risk factor was found for this event.
With respect to our study, we raise the following questions that should be answered in future studies.
Is the lamotrigine therapy responsible for the twin pregnancies in this study? Is the lamotrigine therapy responsible for the vanished twin syndromes in this study? Is the risk of abortion and fetal death with lamotrigine relatively higher than what was estimated before? Because of the small sample size, these questions cannot be answered now. To clarify these issues complementary studies with larger sample sizes could be more informative. 
